The recent guidelines issued by the Central Drugs Standard Control Organization (CDSCO) on compounding minor drug violations mark an important shift in India’s pharmaceutical regulatory framework. They operationalise a legal change set in motion in 2023, aiming to reduce unnecessary criminalisation while retaining regulatory oversight. Yet, whether this reform strengthens compliance or weakens deterrence depends squarely on how transparently and rigorously it is implemented.
What has changed in drug law enforcement
Until recently, even minor or technical non-compliance under the Drugs and Cosmetics Act, 1940 — such as record-keeping lapses or procedural errors — could trigger criminal prosecution. This often led to prolonged litigation, regulatory overload, and a blurring of focus between trivial lapses and serious public health threats.
The new CDSCO guidance introduces standard operating procedures for “compounding” certain offences. Under this mechanism, firms can voluntarily report eligible violations and apply to settle them by paying a prescribed fine, instead of facing criminal proceedings. Once compounding is approved and the amount paid, the firm receives immunity from prosecution for that specific offence, subject to conditions.
The Jan Vishwas Act and the legal backdrop
This regulatory shift flows from the Jan Vishwas (Amendment of Provisions) Act, which sought to “decriminalise and rationalise” a range of minor offences across laws, with the stated objective of improving ease of living and ease of doing business.
In the context of the 1940 Act, Jan Vishwas expanded Section 32B by enlarging the list of compoundable offences. These now include:
- Manufacturing drugs for sale or distribution in breach of the Act, excluding the most serious categories under Section 27(a–c).
- Stocking or exhibiting drugs that are neither spurious nor adulterated but are otherwise non-compliant.
The intent is clear: reserve criminal law for grave violations affecting safety and efficacy, while addressing lesser breaches through proportionate penalties.
Why compounding can be a positive reform
If implemented in good faith, compounding can correct a long-standing imbalance in enforcement. For paperwork-related or disclosure-based offences, it avoids needless criminalisation and allows regulators to redirect attention toward serious violations such as spurious, adulterated, or unsafe drugs.
For industry, it reduces regulatory uncertainty and litigation costs. For regulators, it promises administrative efficiency. In principle, this aligns India’s drug regulation with global practices that favour risk-based enforcement over blanket criminal prosecution.
Concerns about transparency and accountability
The most serious risk is that compounding could degenerate into a “pay and pass” regime. The guidelines allow firms to seek compounding either before or after prosecution, but they do not mandate the publication of compounding orders or even anonymised case summaries.
Without public disclosure, it becomes impossible for independent observers to verify whether:
- Compounding is applied consistently.
- The same firms repeatedly seek immunity.
- Serious violations are being inappropriately downgraded.
Discretion and internal conditions cannot substitute for a publicly auditable trail. Transparency is essential to sustain trust in both the legal process and the regulator.
Scope creep and weak deterrence risks
Another concern lies in how broadly some compoundable errors are defined. In practice, the language could cover a wide spectrum — from clerical mistakes to substantive compliance failures with potential public health implications.
If fines are set too low, applied inconsistently, or used routinely instead of prosecution, the deterrent effect of regulation may erode. Compliance then risks becoming a cost-benefit calculation rather than a non-negotiable obligation.
Why compounding must link to corrective action
For compounding to genuinely improve drug safety, it must be tied to corrective and preventive actions. Immunity from prosecution should not mean immunity from scrutiny.
Effective implementation requires:
- Mandatory corrective action plans.
- Follow-up inspections to verify compliance.
- Public-facing steps where relevant, such as safety alerts or product recalls.
Without this, compounding may resolve cases on paper without reducing long-term risk to patients.
What to note for Prelims?
- CDSCO is India’s national drug regulator.
- Jan Vishwas Act expanded compoundable offences under multiple laws.
- Section 32B of the Drugs and Cosmetics Act governs compounding.
- Compounding offers immunity from prosecution upon payment of a fine.
What to note for Mains?
- Balancing ease of doing business with public health protection.
- Risks of regulatory capture and moral hazard in compounding regimes.
- Need for transparency and public accountability in drug regulation.
- Importance of linking decriminalisation to risk-based enforcement.
The CDSCO’s new guidelines signal a welcome move away from reflexive criminalisation. But unless transparency, proportional penalties, and post-compounding oversight are built into practice, the reform risks weakening — rather than strengthening — India’s pharmaceutical regulatory credibility.
Last Modified: January 10, 2026